|
|
|
28.11.25 - 15:18
|
Eurofins Scientific: Director/PDMR Shareholding (Business Wire)
|
|
|
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below.
This notification is made in accordance with the European Market Abuse Regulation.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1.
Details of the person discharging managerial responsibilities/person closely associated
a)
Name
VIGNEAU François
2.
Reason for the notification
a)
Position / status
Senior Vice President
b)
Initial notification / amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Eurofins Scientific S.E.
b)
LEI
529900JEHFM47DYY3S57
4.
Details of the transaction(s) section to be repeated for (i) each type of instrument; (ii) each type of transaction;...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.11.25 - 17:33
|
Valneva to Further Consolidate its Operations in France (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company's ongoing efforts to increase operational effectiveness and position Valneva for long-term success. ...
|
|
|
26.11.25 - 12:48
|
Valneva: Starke Daten zu Hoffnungsträger – Aktie zieht kräftig an (Der Aktionaer)
|
|
|
Positive Studiennews beflügeln zur Wochenmitte die Aktie des Impfstoffherstellers Valneva. Das Unternehmen hat heute neue positive Ergebnisse aus der Phase-2-Studie zum Impfstoffkandidaten VLA15 gegen Lyme-Borreliose gemeldet. Die Daten zeigen sechs Monate nach der dritten Auffrischung eine starke Immunreaktion in allen Altersgruppen und ein weiterhin gutes Sicherheitsprofil....
|
|
|
|
|
|
|
|
|
26.11.25 - 07:03
|
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate (GlobeNewswire EN)
|
|
|
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed strong anamnestic immune response and favorable safety profile six months after a third booster dose (month 48) in all age groups, confirming compatibility with the anticipated benefits of a yearly vaccination prior to each Lyme season. Pfizer and Valneva entered into a collaboration agreement in April 2020 for the development and commercialization of VLA15 by Pfizer....
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
